Intestinal epithelium impairment in cystic fibrosis: What consequences in clinical practice?
Abstract
Cystic fibrosis (CF) results from the loss of function of the CF transmembrane conductance regulator protein, which is expressed at the apical membrane of various epithelia, including the digestive tract, and involved in chloride and bicarbonate transport. While modulators can improve pulmonary function, digestive symptoms remain a concern for patients with CF. Against this backdrop, it seems important to provide a current overview of research on intestinal inflammation in CF and a detailed analysis of the impact of this inflammation on each intestinal barrier compartment. It would also be useful to offer a description of the consequences of intestinal inflammation on associated complications, such as digestive cancers, and a comprehensive assessment of CF treatments and their impact on digestive manifestations. The different compartments of the intestinal barrier are impaired in CF (gut microbiota, mucus layer, intestinal epithelium, and immune cells), leading to chronic inflammation. This may explain the risk of colorectal cancer.
Related
- CFTR dysfunction in the intestinal epithelium is sufficient to promote pathogenic expansion of E. coli and enhanced barrier permeability in cystic fibrosis
- An improved protocol to isolate enriched immune cells from murine intestinal epithelium and lamina propria
- Evaluation of immunotoxic effects and metabolism of enniatins and beauvericin using in vitro models of the human intestinal epithelium
- From immature to mature epithelium: unveiling structural dynamics and transcriptional programs in rainbow trout intestinal barrier
- IL1B-high macrophages promote ferroptosis-like lipid peroxidation injury in Crohn's disease intestinal epithelium
BibTeX
@article{carle2026intestinal,
title = {{Intestinal epithelium impairment in cystic fibrosis: What consequences in clinical practice?}},
author = {Caroline Carlé and Marie Mittaine and Léa Roditis and Nolwenn Laborde and Frederick Barreau and Emmanuel Mas},
journal = {World Journal of Gastroenterology},
year = {2026},
month = oct,
doi = {10.3748/wjg.121071},
url = {https://hal.inrae.fr/hal-05788534v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Intestinal epithelium impairment in cystic fibrosis: What consequences in clinical practice?
AU - Caroline Carlé
AU - Marie Mittaine
AU - Léa Roditis
AU - Nolwenn Laborde
AU - Frederick Barreau
AU - Emmanuel Mas
PY - 2026
DA - 2026/10/30
JO - World Journal of Gastroenterology
DO - 10.3748/wjg.121071
UR - https://hal.inrae.fr/hal-05788534v1
AB - Cystic fibrosis (CF) results from the loss of function of the CF transmembrane conductance regulator protein, which is expressed at the apical membrane of various epithelia, including the digestive tract, and involved in chloride and bicarbonate transport. While modulators can improve pulmonary function, digestive symptoms remain a concern for patients with CF. Against this backdrop, it seems important to provide a current overview of research on intestinal inflammation in CF and a detailed analysis of the impact of this inflammation on each intestinal barrier compartment. It would also be useful to offer a description of the consequences of intestinal inflammation on associated complications, such as digestive cancers, and a comprehensive assessment of CF treatments and their impact on digestive manifestations. The different compartments of the intestinal barrier are impaired in CF (gut microbiota, mucus layer, intestinal epithelium, and immune cells), leading to chronic inflammation. This may explain the risk of colorectal cancer.
SN - 1007-9327
ER -